Judy C. Boughey, MD, on New Findings on the Impact of Breast Conservation Therapy on Local Recurrence
2022 San Antonio Breast Cancer Symposium
Judy C. Boughey, MD, of Mayo Clinic, talks about why breast-conserving therapy may be a treatment option for some patients with multiple breast lesions. For most patients who present with two or three sites of cancer in one breast, mastectomy is recommended. But results from the ACOSOG Z11102 (Alliance) suggest that for women with multiple ipsilateral breast cancer, breast-conserving surgery with adjuvant radiation therapy and lumpectomy site boosts may be beneficial (Abstract GS4-01).
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Historically, women who have multiple ipsilateral breast cancer have usually been recommended to undergo a mastectomy. And this has been based on historical studies that have shown high rates of local recurrence in patients treated with breast conserving surgery followed by radiation when that patient has two or three or more foci of cancer within the breast.
However, importantly more recent, his single institution retrospective studies have shown more acceptable local recurrence rates with breast conservation therapy in patients with multiple ipsilateral breast cancer. And so because of this, we designed the ACOSOG Z11102 clinical trial. We designed this as a prospective single arm phase two clinical trial, enrolling patients with two or three foci of biopsy proven breast cancer within one breast to be treated with breast conserving therapy. The protocol allowed lumpectomy to be performed via a single or multiple incisions and oncoplastic surgery was allowed. Nodal surgery was required and could be performed by either sentinel node surgery or [inaudible 00:01:11] lymph node dissection.
And then the protocol required whole breast radiation with radiation boost to each of the prior lumpectomy sites. Patients were not allowed to have neoadjuvant therapy on this trial, but all patients with ER positive disease were recommended endocrine therapy and adjuvant systemic therapy was at the discretion of the treating medical oncologist. The patients were followed up every six months for a five-year follow up. The primary endpoint of this trial was to see the five-year estimated local recurrence rate where a clinically acceptable rate determined to be less than 8%. The primary endpoint of this study revealed that the five-year local recurrence rate was 3.1% and the confidence intervals remained below that 8% clinical threshold. So overall, this is a positive study showing that the local recurrence rate is clinically acceptable after breast conserving therapy, which includes lumpectomy followed by whole breast radiation for patients with two or three foci of disease in their breast.
As we look at the study population, vast majority of patients had two foci of breast cancer with only seven patients having three foci of disease. And so as this is implemented into clinical practice, I anticipate that this will be most widely applicable to those patients that have two sites of breast cancer identified on their preoperative workup. This was also limited to patients 40 and older, and the vast majority of patients had clinically node negative disease and had ER positive HER2 negative disease.
Now, the caveat to this is that the number of patients without a preoperative MRI was low with only 15 patients without a preoperative MRI. But we did notice a statistically significant difference in local recurrence with the absence of a use of preoperative MRI. And this was an unplanned secondary analysis, but I think it's judicious to consider preoperative MRI in patients who have two foci disease that where you are considering breast conserving surgery.
Another key finding of this study was that those patients with ER positive disease that did not have adjuvant endocrine therapy had a higher local recurrence rate than those patients that did receive adjuvant endocrine therapy. And this is similar to what we see across all other treatments of breast cancer. And so this reiterates that adjuvant endocrine therapy is an important component of the treatment for patients with multiple ipsilateral breast cancer who are proceeding with breast conserving therapy.
Overall, we think that this study is very exciting and we hope that this will open up breast conserving therapy as an option for more women who are diagnosed with newly diagnosed breast cancer. In particular, those women with two sites of disease where historically many teams may have recommended mastectomy, and now these teams in these patients may consider breast conserving therapy as an option for the patient's shared decision making.
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Patients treated with T-DXd had a 36% lower risk of death than those treated with T-DM1 (Abstract GS2-02).
Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer. Camizestrant, which can be taken as a daily pill (as opposed to fulvestrant, which must be given via injection), improved progression-free survival by up to 42% (Abstract GS3-02).
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for low levels of participation and advocates for capturing the experience of patients not represented in traditional clinical trials, so real-world data can address these validity deficits.
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate (ORR) of 68%. When combined with anastrozole, T-DXd led to a 58% ORR. This is the first trial to evaluate T-DXd in HER2-low breast cancer, a potentially curable disease (Abstract GS2-03).
Marleen Kok, MD, PhD, of the Netherlands Cancer Institute, discusses the most important advances in early breast cancer treatment during the past year for patients with triple-negative, HER2-positive, and estrogen receptor–positive disease. Dr. Kok also addresses long-term treatment toxicities and quality of life.